Antibody and antigen binding fragments thereof
US-2024385186-A1 · Nov 21, 2024 · US
Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
US9902783B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9902783-B2 |
| Application number | US-201615161375-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2016 |
| Priority date | Feb 23, 2007 |
| Publication date | Feb 27, 2018 |
| Grant date | Feb 27, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound having the Formula (I): wherein R is O—CH 2 —CH 2 —CONH—CH 2 —CH 2 —NH 2 . 2. A method of producing a metalloprotein inhibitor, the method comprising: (a) generating antibodies directed at the compound of claim 1 ; and (b) selecting an antibody from said antibodies which is capable of inhibiting the activity of matrix metalloprotein 9 (MMP-9) or matrix metalloprotein 2 (MMP-2), thereby producing the metalloprotein inhibitor. 3. An antibody comprising an antigen recognition region capable of specifically binding the compound of claim 1 and wherein the antibody binds to the catalytic site of MMP-9 and MMP-2 and wherein the antibody is capable of inhibiting the activity of MMP-9 and MMP-2. 4. The antibody of claim 3 , wherein said antigen recognition region comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12. 5. A pharmaceutical composition comprising the antibody of claim 3 as an active agent and a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
specific for metastasis · CPC title
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9902783B2 cover?
- An antibody comprising an antigen recognition region which comprises CDR amino acid sequences set forth in SEQ ID NO: 7, 8, 9, 10, 11 and 12.
- Who is the assignee on this patent?
- Yeda Res & Dev
- What technology area does this patent fall under?
- Primary CPC classification C07K16/44. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).